

PRESS RELEASE

Lund, October 31, 2006

TFS and INSTITUT D'ALTA TECNOLOGIA PRBB FUNDACIO PRIVADA enter agreement in Positron Emission Tomography

INSTITUT D'ALTA TECNOLOGIA PRBB FUNDACIO PRIVADA (IAT-PRBB) and TFS Trial Form Support International (TFS) have as of September 22, 2006 entered into a partnership agreement as regards to Positron Emission Tomography (PET). The purpose of the partnership agreement is to accelerate early clinical development studies where PET can be a suitable imaging technique to shorten the development time and have an early proof of concept.

"We feel proud and privileged to have reached this partnership agreement with IAT-PRBB and we can now increase our activities to meet the need of PET studies in therapeutic areas like CNS, oncology, cardiovascular, endocrinology, pain and many more", says Eva Lundqvist, Director Early Clinical Development at TFS.

IAT-PRBB has currently about 50 projects in the areas of neurology, psychiatry and oncology in molecular image in collaboration with hospitals, pharmaceutical companies and laboratories.

"TFS will now be able to increase the number of PET studies per year. We are today conducting in collaboration with the PET centre at the Karolinska University Hospital about six to seven PET studies annually and mainly in the field of CNS. Now we can increase the numbers rapidly and also be more focused to whole body scan", concludes Eva Lundqvist.

This agreement will enable IAT-PRBB throughout the next years to carry out a series of clinical studies based on the diagnosis by the image, essentially tomography by positron emission (PET) and magnetic resonance (RM), techniques where this center is one of the pioneers in Spain and one of most important in the south of Europe.

As Dr. Francisco Javier Fernández, Managing Director of IAT says, *"we have the latest technology and a multidisciplinary scientist team with noticeable researcher vocation. Both elements make possible our main objective to offer the scientific community and pharmaceutical companies all the services related to molecular imaging for carrying out biomedical investigation, from basic sciences to preclinical and clinical research, and also providing clinical assistance to patients".*



TFS TRIAL FORM SUPPORT

PRESS RELEASE

Information about TFS Trial Form Support (TFS)

TFS is a full-service clinical CRO, providing the pharmaceutical, biotechnological, medical device, diagnostic and functional food industries with a wide range of clinical trial services. TFS services cover the whole clinical development programme from early explorative Phase I trials to registration trials in Phases II-III and post marketing surveillance trials in Phase IV. The 300 highly competent employees dedicated to accuracy and service has made TFS one of the fastest growing CROs in Europe with multiple offices spread throughout Sweden, Denmark, Finland, Norway, the United Kingdom, Spain, Italy, Portugal, Russia, the Baltic States, India and Japan.

Information about IAT-PRBB

The IAT-PRBB is a private foundation impelled by CRC Sea and the Municipal Institute of Asistencia Sanitaria (IMAS) and managed by CRC Corporació Sanitària that applies techniques of molecular image in the biomedical investigation. Integrated in the IAT-PRBB - 80 groups of biomedical investigations, its objective is to become a center of investigation in south of Europe to the height of similar centers that work in the United Kingdom, Sweden or Finland. The IAT counts on the scientific support of the Municipal Institute of Medical Researches (IMIM), the Institute of Biomedical Investigations August Pi i Sunyer (IDIBAPS) and the Fundació Institut de Recerca Hospital Universitari Vall d' Hebron.

For further information please contact:
Daniel Spasic, Chief Executive Officer
TFS Trial Form Support International AB
Telephone: + 46 (0)8 – 440 76 00



TFS TRIAL FORM SUPPORT